Effects of IFN-γ on cardiac hypertrophy
AssigneeGenentech, Inc.
InventorsHongkui Jin, Hsienwie Lu, Nicholas F. Paoni, Renhui Yang
Life of this patent
Estimating the term…
Abstract
The invention concerns the treatment of cardiac hypertrophy by interferon-gamma (IFN-γ). Cardiac hypertrophy may result from a variety of diverse pathologic conditions, including myocardial infarction, hypertension, hypertrophic cardiomyopathy, and valvular regurgitation. The treatment extends to all stages of the progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder.
Claims21
A method for reducing the weight of heart in a patient diagnosed with cardiac hypertrophy, comprising administering to the patient an effective amount of interferon gamma (IFN-γ).
A method for preventing or reducing an increase in the weight of heart of a patient at acute risk of developing cardiac hypertrophy, comprising administering to the patient an effective amount of interferon gamma (IFN-γ).
Dependencies are inferred from the claim text.